Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 2Uterine Cervical Dysplasia 1Sarcoma 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Hodgkin Disease 1Central Nervous System Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 4anlotinib 4sintilimab 3Paclitaxel 3Leucovorin 3Cetuximab 3niraparib 2Sorafenib 2Radiotherapy 2Nivolumab 2Hyperthermic Intraperitoneal Chemotherapy 2Gemcitabine 2Fluorouracil 2Drug Therapy 2Docetaxel 2Cisplatin 2vistusertib 1titanium silicide 1tislelizumab 1tirbanibulin 1surufatinib 1regorafenib 1pemigatinib 1olaparib 1elemene 1durvalumab 1donafenib 1daromun 1avelumab 1aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma × Ocoxin × Clear all
NCT03549273 2024-02-07

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Catalysis SL

Phase 2 Unknown
62 enrolled
Gynecologic

Carcinoma, Uterine Cervical Dysplasia, Neoplasms, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡